Banque Transatlantique SA Takes $533,000 Position in Insmed, Inc. $INSM

Banque Transatlantique SA acquired a new position in shares of Insmed, Inc. (NASDAQ:INSM) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 3,708 shares of the biopharmaceutical company’s stock, valued at approximately $533,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. EULAV Asset Management purchased a new stake in Insmed during the third quarter worth approximately $12,961,000. Resolute Capital Asset Partners LLC acquired a new position in Insmed in the second quarter valued at approximately $2,748,000. Nisa Investment Advisors LLC increased its stake in Insmed by 374.6% in the third quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock valued at $1,507,000 after purchasing an additional 8,261 shares during the last quarter. Keybank National Association OH raised its holdings in Insmed by 76.7% during the third quarter. Keybank National Association OH now owns 16,716 shares of the biopharmaceutical company’s stock worth $2,407,000 after purchasing an additional 7,257 shares in the last quarter. Finally, Atika Capital Management LLC acquired a new stake in Insmed during the third quarter worth approximately $13,681,000.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $139.50 on Friday. The firm has a market capitalization of $30.07 billion, a price-to-earnings ratio of -21.76 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The business’s 50 day simple moving average is $155.18 and its 200-day simple moving average is $165.70. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The firm had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business’s revenue for the quarter was up 152.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.32) earnings per share. As a group, equities analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $146.03, for a total value of $1,562,374.97. Following the sale, the chief executive officer directly owned 301,185 shares in the company, valued at $43,982,045.55. The trade was a 3.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Roger Adsett sold 791 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total transaction of $123,530.47. Following the transaction, the chief operating officer owned 106,810 shares of the company’s stock, valued at $16,680,517.70. This trade represents a 0.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 189,651 shares of company stock valued at $31,784,545 over the last 90 days. 3.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

INSM has been the subject of several research analyst reports. Barclays assumed coverage on shares of Insmed in a report on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 target price for the company. Mizuho cut their price target on shares of Insmed from $211.00 to $204.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 24th. HC Wainwright reissued a “buy” rating and issued a $230.00 price target on shares of Insmed in a research report on Monday, February 23rd. The Goldman Sachs Group upped their price objective on shares of Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Roth Mkm raised Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $207.52.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.